BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data

BioVie Announces $4.74 Million Registered Direct Offering and Concurrent Private Placement

BioVie Inc. has entered into a securities purchase agreement to raise approximately $4.74 million through the sale of 2,962,500 shares of common stock at $1.60 per share.

BioVie Invited To Present Late-Breaking Oral Presentation At The 4th Long Covid International Conference, November 12-13

BioVie Invited to Present Data on Bezisterim at NIH's RECOVER-TLC Workshop

BioVie Inc. has been invited to present clinical data on its investigational therapy, bezisterim, at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.

BioVie shares are trading higher after the company announced the presentation of Phase 2 Long COVID data showing statistically significant improvements in fatigue and cognitive measures in certain patient subgroups treated with bezisterim.

BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association

BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of

BioVie To Present Phase 2 Bezisterim Data In Long COVID, Parkinson’s At Neurology Conference October 18-19